New CAR t therapy targets three tough cancers in early trial

NCT ID NCT05568680

First seen Nov 01, 2025 · Last updated May 04, 2026 · Updated 30 times

Summary

This early-stage study tests a one-time treatment called SynKIR-110, made from a patient's own immune cells modified to attack cancer cells that have a protein called mesothelin. It is for adults with advanced ovarian cancer, bile duct cancer, or mesothelioma that has come back after standard treatment. The main goals are to check safety and find the best dose, not to cure the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Kansas Cancer Center

    RECRUITING

    Westwood, Kansas, 66205, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Pennsylvania

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Wisconsin Carbone Cancer Center

    RECRUITING

    Madison, Wisconsin, 53792, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.